BAKER BROS. ADVISORS LP
Q3 2023 13F-HR Holdings
Net value change ($000)
+71,796
(0.4%)
New positions
8
Sold out positions
15
Turnover %
1.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Seagen Inc. | 877,271 | 10.2% |
| RYTM | 46,495 | 43.4% |
| ROIV | 43,685 | 46.0% |
| ONC | 18,321 | 0.9% |
| IMVT | 16,316 | NEW |
| RARE | 12,594 | 34.9% |
| Mirati Therapeutics, Inc. | 10,475 | 20.6% |
| KNSA | 9,243 | 23.4% |
| AKRO | 9,213 | 8.3% |
| ARVN | 8,121 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| INCY | -162,048 | -7.2% |
| ACAD | -133,308 | -13.0% |
| MDGL | -131,273 | -36.8% |
| KOD | -88,283 | -73.9% |
| CHINOOK THERAPEUTICS, INC. | -55,909 | -100.0% |
| DICE Therapeutics, Inc. | -48,123 | -100.0% |
| ARGX | -34,844 | -31.9% |
| KYMR | -34,558 | -34.4% |
| ImmunoGen, Inc. | -28,684 | -100.0% |
| REPL | -27,974 | -26.3% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|